Bronchitis - Drug Pipeline Analysis and Market Forecasts to 2016

07 Jun 2010 • by Natalie Aster

GlobalData, the industry analysis specialist, has released its latest research “Bronchitis- Drug Pipeline Analysis and Market Forecasts to 2016”. The report provides key data, information and analysis on the bronchitis market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The report provides coverage of the market landscape, market drivers and restraints, and an in-depth pipeline analysis. The current competitive landscape is also analyzed and the unmet need and commercial opportunity of the market is calculated. The pipeline analysis covers molecules across all phases of clinical development and provides an overview of the developing trends among the pipeline molecules, as well as an insight into the most promising pipeline drugs supplemented with key company profiles. By considering the current competition in the market and the prospects of the pipeline molecules, the resulting implications for the future market competition are also outlined.

The Bronchitis Market is Estimated to grow at 3.7% Compounded Annual Growth Rate from 2009 to 2016

The global bronchitis market was valued at $482m in 2009 and is forecast to grow by 3.7% annually for the next seven years to reach $622m in 2016. The typical form of bronchitis is self-limited. The bronchitis market is characterized by many generics and OTC. The NSAIDS, cough suppressants and antipyretics are mere supportive therapies. Antibiotics are highly prescribed to treat atypical form of the disease. The increase in the market size is attributed to the increase in incidence and increase in the up take of cost effective drugs.

As the Disease is Self-Limited the Drug are employed as mere supportive therapies.

Typically virus is the major cause of bronchitis. The typical bronchitis is symptomatically treated with NSAIDS, cough suppressants and antipyretics. As the human immune system is capable of eliminating the pathogens, the scope of application of drugs remains limited. In the atypical form of the disease antibiotics are employed to treat the infection.

Bronchitis is one of the common causes for the hospitalization of infants and children in the developed economies. Though there are no drugs to treat the disease, the infants require hospitalization to prevent them from acquiring sever form of the other disease like pneumonia or lower respiratory infections.

The Weak pipeline consists of only 13molecules

There are 13 molecules in the various phases of the developmental pipeline. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The antibiotics in the pipeline are generic. Upon approval they will add to the competition. The phase of the pipeline consists of levefloxacin and Merck’s Singulair. Upon approval they are expected to intensify the competition.

Current Treatment Options Satisfactorily Serve the Market Needs and are Curative

As the disease is self-limited, it is treated only symptomatically. The NSAIDS, cough suppressants, antipyretics are employed by the medical practitioners to treat the symptoms of the disease. With time the disease cured by human immune system itself. In minority of the cases, the disease is caused by bacteria called atypical bronchitis. Atypical bronchitis is treated by antibiotics.

Bronchiolitis is caused by RSV and mostly affects children and infant. The infants require hospitalization while children are treated as out patients. With time the human immune system eliminates the pathogens. Similar to bronchitis, the patients are treated with NSAIDS, cough suppressants, antipyretics and expectorants. The most sever of the bronchitis leads to bronchial constriction and may lead to COPD. At preset the treatment options satisfactorily demands

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.